Oncternal Therapeutics, Inc. announced the initiation of its Phase 3 global registrational study of zilovertamab, ZILO-301 (NCT05431179), for the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL). The Company obtained its first Institutional Review Board (IRB) approval for the study and expects to promptly begin patient screening and enrollment.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.875 USD | +2.96% | +2.86% | -17.94% |
May. 09 | Transcript : Oncternal Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Oncternal Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.94% | 25.51M | |
+29.21% | 49.18B | |
+0.84% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.29% | 26.09B | |
-22.70% | 18.71B | |
+8.11% | 13.26B | |
+32.02% | 12.32B | |
-0.63% | 11.99B |
- Stock Market
- Equities
- ONCT Stock
- News Oncternal Therapeutics, Inc.
- Oncternal Therapeutics, Inc Initiates Global Registrational Phase 3 Study of Zilovertamab for Patients with MCL